JPWO2020184691A1 - - Google Patents

Info

Publication number
JPWO2020184691A1
JPWO2020184691A1 JP2021505150A JP2021505150A JPWO2020184691A1 JP WO2020184691 A1 JPWO2020184691 A1 JP WO2020184691A1 JP 2021505150 A JP2021505150 A JP 2021505150A JP 2021505150 A JP2021505150 A JP 2021505150A JP WO2020184691 A1 JPWO2020184691 A1 JP WO2020184691A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021505150A
Other languages
Japanese (ja)
Other versions
JPWO2020184691A5 (US06244707-20010612-C00010.png
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020184691A1 publication Critical patent/JPWO2020184691A1/ja
Publication of JPWO2020184691A5 publication Critical patent/JPWO2020184691A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2021505150A 2019-03-12 2020-03-12 Withdrawn JPWO2020184691A1 (US06244707-20010612-C00010.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019044670 2019-03-12
PCT/JP2020/010967 WO2020184691A1 (ja) 2019-03-12 2020-03-12 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法

Publications (2)

Publication Number Publication Date
JPWO2020184691A1 true JPWO2020184691A1 (US06244707-20010612-C00010.png) 2020-09-17
JPWO2020184691A5 JPWO2020184691A5 (US06244707-20010612-C00010.png) 2022-01-27

Family

ID=72426033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505150A Withdrawn JPWO2020184691A1 (US06244707-20010612-C00010.png) 2019-03-12 2020-03-12

Country Status (15)

Country Link
US (1) US20220218664A1 (US06244707-20010612-C00010.png)
EP (1) EP3939659A4 (US06244707-20010612-C00010.png)
JP (1) JPWO2020184691A1 (US06244707-20010612-C00010.png)
KR (1) KR20220009371A (US06244707-20010612-C00010.png)
CN (1) CN114126711A (US06244707-20010612-C00010.png)
AU (1) AU2020238177A1 (US06244707-20010612-C00010.png)
BR (1) BR112021018084A8 (US06244707-20010612-C00010.png)
CA (1) CA3133204A1 (US06244707-20010612-C00010.png)
CL (1) CL2021002373A1 (US06244707-20010612-C00010.png)
EA (1) EA202192483A1 (US06244707-20010612-C00010.png)
IL (1) IL286289A (US06244707-20010612-C00010.png)
MX (1) MX2021011007A (US06244707-20010612-C00010.png)
PE (1) PE20220333A1 (US06244707-20010612-C00010.png)
SG (1) SG11202109982YA (US06244707-20010612-C00010.png)
WO (1) WO2020184691A1 (US06244707-20010612-C00010.png)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220040294A (ko) * 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
WO2022171151A1 (zh) * 2021-02-10 2022-08-18 上海森辉医药有限公司 一种smtp-7衍生物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05176782A (ja) * 1992-01-08 1993-07-20 Taisho Pharmaceut Co Ltd Ngf作用増強因子
JP4313049B2 (ja) * 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
US20090270476A1 (en) 2005-10-06 2009-10-29 Keiji Hasumi Pharmaceutical composition for treatment or prevention of nephritis and manufacturing method thereof
CN102321092B (zh) 2006-03-27 2015-01-14 农工大Tlo株式会社 三异戊二烯基酚化合物、三异戊二烯基酚化合物的制造方法和血栓溶解促进剂
WO2010110026A1 (ja) * 2009-03-25 2010-09-30 国立大学法人東京農工大学 メタボリックシンドローム、肥満、高血糖症、高脂血症および/又は脂肪肝のための医薬組成物
ES2476041T3 (es) * 2009-07-06 2014-07-11 National University Corporation Tokyo University Of Agriculture And Technology Agente citoprotector trifenilfen�lico
WO2011125930A1 (ja) * 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
JP2019044670A (ja) 2017-08-31 2019-03-22 スズキ株式会社 内燃機関の排出ガス浄化システム

Also Published As

Publication number Publication date
KR20220009371A (ko) 2022-01-24
CL2021002373A1 (es) 2022-06-17
MX2021011007A (es) 2022-03-11
CN114126711A (zh) 2022-03-01
EP3939659A4 (en) 2022-12-21
US20220218664A1 (en) 2022-07-14
AU2020238177A1 (en) 2021-11-04
PE20220333A1 (es) 2022-03-14
CA3133204A1 (en) 2020-09-17
BR112021018084A2 (US06244707-20010612-C00010.png) 2021-12-21
SG11202109982YA (en) 2021-10-28
EA202192483A1 (ru) 2021-12-24
EP3939659A1 (en) 2022-01-19
BR112021018084A8 (pt) 2022-10-04
IL286289A (en) 2021-10-31
WO2020184691A1 (ja) 2020-09-17

Similar Documents

Publication Publication Date Title
BR112019017762A2 (US06244707-20010612-C00010.png)
BR112021017339A2 (US06244707-20010612-C00010.png)
BR112021013854A2 (US06244707-20010612-C00010.png)
BR112021018450A2 (US06244707-20010612-C00010.png)
BR112021017939A2 (US06244707-20010612-C00010.png)
BR112021017892A2 (US06244707-20010612-C00010.png)
BR112019016141A2 (US06244707-20010612-C00010.png)
BR112021017738A2 (US06244707-20010612-C00010.png)
BR112021017782A2 (US06244707-20010612-C00010.png)
BR112019016138A2 (US06244707-20010612-C00010.png)
BR112019016142A2 (US06244707-20010612-C00010.png)
BR112021018168A2 (US06244707-20010612-C00010.png)
BR112021017728A2 (US06244707-20010612-C00010.png)
BR112021008711A2 (US06244707-20010612-C00010.png)
BR112021017234A2 (US06244707-20010612-C00010.png)
BR112021017355A2 (US06244707-20010612-C00010.png)
BR112021017173A2 (US06244707-20010612-C00010.png)
BR112021018102A2 (US06244707-20010612-C00010.png)
BR112021017083A2 (US06244707-20010612-C00010.png)
BR112021017637A2 (US06244707-20010612-C00010.png)
BR112021018452A2 (US06244707-20010612-C00010.png)
BR112021012348A2 (US06244707-20010612-C00010.png)
BR112021018250A2 (US06244707-20010612-C00010.png)
BR112021018093A2 (US06244707-20010612-C00010.png)
BR112021018084A2 (US06244707-20010612-C00010.png)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210910

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211206

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230308

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230928